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Figure: Cumulative incidence of major adverse cardiovascular events in the two
study groups.
Conclusion: Glycemic control, determined by HbA1c, does not seem to influence 12-
month cardiovascular outcomes in DM with AMI after successful PCI.
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Background: We prospectively investigated the effects of pioglitazone in reducing
MACEs after zotarolimus-eluting stent (ZES) implantation in type 2 diabetic patients
with significant coronary artery narrowing during the 3-year follow-up.
Methods: Type 2 diabetic patients with coronary artery diseases were randomly
assigned to pioglitazone (n=91) or placebo (n=114) after ZES implantation. Primary
endpoint was to compare MACEs such as non-fatal myocardial infarction, death,
stroke, and target lesion revascularization (TLR) between the 2 groups during the 3-
year follow-up. Secondary endpoints were to compare rates of new-onset heart failure,
fracture, and non-TLR target vessel revascularization (TVR) between the 2 groups.
Results: MACEs were significantly higher in the placebo group than the pioglitazone
group during the follow-up [hazard ratio 2.326 (95% CI 1.167-4.638), p=0.016] (Figure
1). Rates of non-fatal myocardial infarction [odds ratio (OR) 1.011 (95% CI 0.989-
1.033)], death [OR 0.974 (95% CI 0.945-1.004)], and stroke [OR 2.537 (95% CI
0.227-28.456)] showed no significant differences between the 2 groups; however, TLR
[OR 0.322 (95% CI 0.144-0.721)] was significantly lower in the pioglitazone group
than the placebo group. Rates of new-onset heart failure [OR 2.222 (95% CI 0.776-
6.365)], fracture [OR 1.636 (95% CI 0.618-4.331)] and non-TLR TVR [OR 1.261
(95% CI 0.248-6.403)] revealed no significant differences between the 2 groups.
Conclusion: Rates of MACEs were significantly lower in the pioglitazone group when
compared with the placebo group, mainly due to the lower rate of TLR during the 3-
year follow-up.
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Background: International guidelines recommend the use of drug eluting stents in all
diabetics, regardless of other restenosis risk factors. However, bare metal stents (BMS)
are generally a safe and effective treatment option for low risk of restenosis lesions
(LR lesions). Hence, we analyzed results of diabetics undergoing percutaneous
coronary intervention (PCI) for LR lesions treated with BMS.
Methods: The study population is a single center prospective cohort that underwent
non-urgent PCI between 2003 and 2007. LR lesions were defined as a reference vessel
diameter≥3.0 mm and lesion length≤15 mm. All cardiac events were collected up to 1
year of follow-up. Patients treated with BMS were stratified as no(noDM), non-insulin
requiring (NIRDM) and insulin requiring (IRDM) diabetics. Cumulative event rates
were estimated with the Kaplan-Meier method and compared with a log-rank test.
Results: We included a total of 1951 patients; 1596 noDM, 231 NIRDM, and 124
IRDM. Target lesion revascularization (TLR) rates in non-DM versus NIRDM were
similar (6.3% vs. 5.6%; p=0.68), while TLR in IRDM was higher (6.3% vs. 14.4%;
p=0.03) (Figure). The composite of cardiac death, myocardial infarction and target
vessel revascularization was not significantly different in non-DM versus NIRDM
(9.5% vs. 13.4%; p=0.07), though in IRDM it was higher (9.5% vs. 17.7; P<0.01).
Conclusion: The results implicate that BMS placement may be considered in patients
with NIRDM and LR lesions. Further work is required to define treatment strategies
and, more importantly, improve the outcomes in diabetics.
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Background: The incidence of contrast induced acute kidney injury (CI-AKI)
following coronary angiography/PCI in patients with DM may be up to 30% and is
associated with increased long term morbidity/mortality. Patients with CKD are
excluded from the majority of cardiology trials and are at high risk for development
of CI-AKI. We aimed to identify whether a panel of novel biomarkers could predict
CI-AKI early post procedure allowing earlier identification of affected patients. We
also assessed severity of CAD and whether this influenced the development of CI-
AKI.
Methods: We recruited 208 consecutive patients undergoing elective/urgent coronary
angiography/PCI with known DM and CKD (eGFR <60ml/min). CI-AKI was defined
as a rise in creatinine at day 3 of >25% from baseline or an absolute rise of 44.5μmol/l.
Severity of CAD was assessed by the SYNTAX Score and risk of CI-AKI using the
Mehran score. We evaluated serum and urine NGAL and Il-18 and albuminuria for
additional information about CI-AKI risk. NAC and iv hydration were given to all
patients with eGFR <50 ml/min in accordance with local guidelines.
Results: 116 patients underwent coronary angiography and 92 PCI. 39 patients (18.8%)
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